Macrovascular complications in diabetes

Macrovascular complications in diabetes refer to cardiovascular diseases (CVD) that arise due to the prolonged effects of hyperglycaemia on the large blood vessels. These complications typically involve the coronary arteries, cerebral vessels, and peripheral arteries. Patients with diabetes have an increased risk of developing atherosclerosis, which leads to cardiovascular events such as heart attacks, strokes, and peripheral arterial disease (PAD).

Pathophysiology

The development of macrovascular complications in diabetes is primarily driven by the following mechanisms:

- Chronic hyperglycaemia - high blood glucose levels promote the formation of advanced glycation end-products (AGEs), which increase vascular stiffness, damage the endothelial cells, and promote the inflammatory response. This leads to the accumulation of lipids and fibrous tissue in the arterial walls, contributing to atherosclerosis.
- Insulin resistance - insulin resistance leads to increased levels of free fatty acids, which further worsen endothelial dysfunction and accelerate atherogenesis.
- Dyslipidaemia - people with diabetes often have abnormal lipid profiles usually with elevated triglycerides, low HDL cholesterol, and raised small, dense LDL cholesterol - all of which are risk factors for atherosclerosis.
- Hypertension - high blood pressure is a common comorbidity and contributes to endothelial injury and the formation of atherosclerotic plaques.

Risk factors

Several factors increase the risk of macrovascular complications in diabetes:

- Duration of diabetes - the longer a person has diabetes, the higher their risk.
- Poor glycaemic control - chronic hyperglycaemia accelerates the development of vascular damage.
- Hypertension - uncontrolled high blood pressure significantly increases the risk of CVD.
- Dyslipidaemia - abnormal lipid levels further contribute to the atherosclerotic process.
- Obesity - central obesity, a common feature in Type 2 diabetes, is closely linked to insulin resistance and increased cardiovascular risk.
- Smoking - smoking exacerbates endothelial dysfunction and accelerates the process of atherosclerosis.
- Family history - a genetic predisposition to cardiovascular disease increases the likelihood of macrovascular complications.

Clinical manifestations

Macrovascular complications may present with the following conditions:

- Coronary Artery Disease (CAD) - People with diabetes are at an increased risk of myocardial infarction (heart attack). The presence of CAD may be asymptomatic until an acute event occurs, but symptoms include chest pain- especially on exertion (angina), shortness of breath, and fatigue.

By **Dr Amar Puttanna** MBChB MRCP

- Cerebrovascular Disease (CVD) - Diabetes increases the risk of stroke, both ischemic (blockage of blood vessels) and haemorrhagic (bleeding from blood vessels). Symptoms include sudden numbness, weakness, confusion, difficulty speaking, or vision changes.
- Peripheral Arterial Disease (PAD) - PAD results from reduced blood flow to the limbs, leading to symptoms such as leg pain, cramping, and non-healing wounds. Severe cases can result in gangrene and require amputation.

Diagnosis

Diagnosis of macrovascular complications typically involves:

- Clinical assessment - history of cardiovascular symptoms, risk factors, and physical examination findings.
- Electrocardiogram (ECG) and (if needed) stress testing for suspected CAD.
- Carotid Doppler ultrasound or CT angiography to evaluate cerebrovascular disease if symptoms present.
- Ankle-brachial index (ABI) to diagnose PAD, along with imaging studies like Doppler ultrasound or angiography if necessary.

Prevention and management

- Glycaemic control - tight control of blood glucose (maintaining HbA1c below 7%) is important l for preventing Glycaemic control - optimal control of blood glucose levels through lifestyle modification, non-insulin medications, and/or insulin therapy is essential to reduce the risk of macrovascular complications.
- Blood pressure management - maintaining blood pressure within recommended levels (typically <140/90 mmHg) with medications such as ACE inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers can reduce cardiovascular risk.
- Lipid control - Statins and other lipid-lowering therapies (such as ezetimibe or PCSK9 inhibitors) are used to manage dyslipidaemia and reduce the risk of cardiovascular events.
- Aspirin therapy - low-dose aspirin may be considered for secondary prevention of cardiovascular events in high-risk patients, but its use should be evaluated based on individual risk factors.
- Lifestyle modifications - smoking cessation, regular physical activity, and a healthy diet offer benefit in managing macrovascular risk.
- Monitoring - regular follow-up visits are important to monitor:
    - Glycemic control through HbA1c levels.
    - Blood pressure through regular measurements.
    - Lipid profile to assess dyslipidemia.
    - Renal function to detect any diabetic nephropathy, which can exacerbate cardiovascular risk.

Summary

Macrovascular complications are a leading cause of morbidity and mortality in patients with diabetes. Effective management of blood glucose, blood pressure, and lipids, alongside lifestyle changes, can significantly reduce the risk of these complications. Early detection and intervention are critical to improving long-term outcomes and preventing cardiovascular events in diabetic patients.

References

- Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12
- Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care. 1987 Jan-Feb;10(1):1-19
- King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643-8
- Beckman JA, Creager MA. Vascular Complications of Diabetes. Circ Res. 2016 May 27;118(11):1771-85.